These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37596982)

  • 1. Pharmacokinetics and optimized dosing of dispersible and non-dispersible levofloxacin formulations in young children.
    van der Laan LE; Hesseling AC; Schaaf HS; Palmer M; Draper HR; Wiesner L; Denti P; Garcia-Prats AJ
    J Antimicrob Chemother; 2023 Oct; 78(10):2481-2488. PubMed ID: 37596982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.
    Denti P; Garcia-Prats AJ; Draper HR; Wiesner L; Winckler J; Thee S; Dooley KE; Savic RM; McIlleron HM; Schaaf HS; Hesseling AC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis.
    White YN; Solans BP; Denti P; van der Laan LE; Schaaf HS; Vonasek B; Malik AA; Draper HR; Hussain H; Hesseling AC; Garcia-Prats AJ; Savic RM
    Clin Infect Dis; 2024 Mar; 78(3):756-764. PubMed ID: 38340060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure.
    Garcia-Prats AJ; Purchase SE; Osman M; Draper HR; Schaaf HS; Wiesner L; Denti P; Hesseling AC
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paediatric formulations of artemisinin-based combination therapies for treating uncomplicated malaria in children.
    Bélard S; Ramharter M; Kurth F
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD009568. PubMed ID: 33289099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acceptability of levofloxacin dispersible and non-dispersible tablet formulations in children receiving TB preventive treatment.
    Wademan DT; Draper HR; Purchase SE; Palmer M; Hesseling AC; Van der Laan L; Garcia-Prats AJ
    IJTLD Open; 2024 Feb; 1(2):69-75. PubMed ID: 38966689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
    Waalewijn H; Chan MK; Bollen PDJ; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Sarfati T; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Moore CL; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM;
    Lancet HIV; 2022 May; 9(5):e341-e352. PubMed ID: 35189082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing dosing of the cycloserine pro-drug terizidone in children with rifampicin-resistant tuberculosis.
    van der Laan LE; Garcia-Prats AJ; McIlleron H; Abdelwahab MT; Winckler JL; Draper HR; Wiesner L; Schaaf HS; Hesseling AC; Denti P
    Antimicrob Agents Chemother; 2023 Dec; 67(12):e0061123. PubMed ID: 37971239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study.
    Denti P; Wasmann RE; van Rie A; Winckler J; Bekker A; Rabie H; Hesseling AC; van der Laan LE; Gonzalez-Martinez C; Zar HJ; Davies G; Wiesner L; Svensson EM; McIlleron HM
    Clin Infect Dis; 2022 Aug; 75(1):141-151. PubMed ID: 34665866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.
    Schipani A; Pertinez H; Mlota R; Molyneux E; Lopez N; Dzinjalamala FK; van Oosterhout JJ; Ward SA; Khoo S; Davies G
    Br J Clin Pharmacol; 2016 Apr; 81(4):679-87. PubMed ID: 26613187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children.
    Radtke KK; Hesseling AC; Winckler JL; Draper HR; Solans BP; Thee S; Wiesner L; van der Laan LE; Fourie B; Nielsen J; Schaaf HS; Savic RM; Garcia-Prats AJ
    Clin Infect Dis; 2022 Apr; 74(8):1372-1381. PubMed ID: 34286843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling.
    Zou Y; Nedelman J; Lombardi A; Pappas F; Karlsson MO; Svensson EM
    Clin Pharmacokinet; 2022 Nov; 61(11):1585-1593. PubMed ID: 36180816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects.
    Abdulla S; Amuri B; Kabanywanyi AM; Ubben D; Reynolds C; Pascoe S; Fitoussi S; Yeh CM; Nuortti M; Séchaud R; Kaiser G; Lefèvre G
    Malar J; 2010 Sep; 9():253. PubMed ID: 20815879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses.
    Zvada SP; Denti P; Donald PR; Schaaf HS; Thee S; Seddon JA; Seifart HI; Smith PJ; McIlleron HM; Simonsson US
    J Antimicrob Chemother; 2014 May; 69(5):1339-49. PubMed ID: 24486870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
    Bollen PDJ; Moore CL; Mujuru HA; Makumbi S; Kekitiinwa AR; Kaudha E; Parker A; Musoro G; Nanduudu A; Lugemwa A; Amuge P; Hakim JG; Rojo P; Giaquinto C; Colbers A; Gibb DM; Ford D; Turkova A; Burger DM;
    Lancet HIV; 2020 Aug; 7(8):e533-e544. PubMed ID: 32763217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acceptability of a Novel Levofloxacin Dispersible Tablet Formulation in Young Children Exposed to Multidrug-resistant Tuberculosis.
    Purchase SE; Garcia-Prats AJ; De Koker P; Draper HR; Osman M; Seddon JA; Schaaf HS; Hesseling AC
    Pediatr Infect Dis J; 2019 Jun; 38(6):608-610. PubMed ID: 30550511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis.
    Bjugård Nyberg H; Draper HR; Garcia-Prats AJ; Thee S; Bekker A; Zar HJ; Hooker AC; Schaaf HS; McIlleron H; Hesseling AC; Denti P
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Low- and High-Mineral Content Water on the Relative Bioavailability of a Coformulated Abacavir/Dolutegravir/Lamivudine Dispersible Tablet in Healthy Adults.
    Singh RP; Shaik JSB; Skoura N; Joshi S; Shreeves T; Casillas L; Buchanan AM
    J Acquir Immune Defic Syndr; 2018 Dec; 79(5):631-638. PubMed ID: 30239425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics.
    Kovarik JM; Noe A; Berthier S; McMahon L; Langholff WK; Marion AS; Hoyer PF; Ettenger R; Rordorf C
    J Clin Pharmacol; 2003 Feb; 43(2):141-7. PubMed ID: 12616666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.